

Ulcerative Colitis

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Trial Status
Completed

Trial Runs In
23 Countries

Trial Identifier
NCT04090411 TL1A,Tuscany
2,2019-002698-74 B7541007

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.

Hoffmann-La Roche
Sponsor

Phase 2
Phase

NCT04090411 TL1A,Tuscany 2,2019-002698-74 B7541007
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years & ≤ 75 Years

Healthy Volunteers
No
